

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 30, 2022**

**Enovis Corporation**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34045**  
(Commission  
File Number)

**54-1887631**  
(I.R.S. Employer  
Identification No.)

**2711 Centerville Road, Suite 400**  
**Wilmington, DE 19808**  
(Address of principal executive offices) (Zip Code)

**(302) 252-9160**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, par value \$0.001 per share</b>	<b>ENOV</b>	<b>New York Stock Exchange</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 30, 2022, Enovis Corporation (the “Company”) announced that Christopher M. Hix will retire from his position as the Company’s Executive Vice President and Chief Financial Officer and cease to serve as the Company’s principal financial officer on December 31, 2022. At that time, Mr. Hix will transition to an advisory role until his retirement in the fourth quarter of 2023.

Upon Mr. Hix’s retirement from his current position, on January 1, 2023, the Company expects to appoint Phillip Benjamin (Ben) Berry, the current chief financial officer of the Company’s business units, as its new chief financial officer and principal financial officer.

Mr. Berry, 44, joined the Company in 2020, initially serving as chief financial officer of the Company’s medical technology segment, and serving as chief financial officer of those business units following the separation of the Company’s fabrication technology business on April 4, 2022. Previously, he spent 18 years in the medical technologies sector with Alcon, which included its launch as an independent public company. During his tenure at Alcon, Mr. Berry served in finance leadership roles of increasing responsibility in strategy, operations and business process improvement. Mr. Berry holds a master’s degree in business administration from Kennesaw State University.

A copy of the Company’s press release regarding these events is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

99.1 [Press release dated June 30, 2022](#)

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 30, 2022

**ENOVIS CORPORATION**

By: /s/ Bradley J. Tandy

Name: Bradley J. Tandy

Title: Senior Vice President and General Counsel



### **Enovis Announces Chief Financial Officer Transition Plan**

Wilmington, Delaware, June 30, 2022 — Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that Ben Berry, CFO of the Company's business units, will succeed Chris Hix as Chief Financial Officer, effective January 1, 2023. At that time, Mr. Hix will transition to an advisory role until his retirement in the fourth quarter of 2023.

Matt Trerotola, Enovis Chief Executive Officer, stated, "Ben has demonstrated strong financial leadership in the medical technology space over his 21-year career. Since joining us in 2020, he has strengthened our financial teams and processes, while making significant contributions to the Company's improved operating performance and profit margins. He has also played a key role in shaping our growth strategy, including acquisitions. We look forward to Ben's continued contributions to our future success in his new role."

Mr. Trerotola continued, "It has been a privilege to work with Chris for the past six years, and we wish him all the best as he transitions into retirement. His deep experience, leadership, and commitment to excellence have been instrumental in the execution of our operating plans and transformation of the Company into a pure-play, medical technology leader. All of us at Enovis value his outstanding financial stewardship, thoughtful guidance, and strong engagement and will benefit from his valuable counsel to ensure a seamless transition."

Mr. Hix joined the Company in 2016 as CFO. During his tenure, the Company transformed its portfolio of businesses by improving operating performance, acquiring a medical technology growth business platform, successfully divesting cyclical industrial businesses, and separating the remaining Company into two independent public companies with distinctive paths for significant shareholder value creation.

Previously, Mr. Berry spent 18 years in the medical technologies sector with Alcon, which included its launch as an independent public company. During his tenure, he served in finance leadership roles of increasing responsibility in strategy, operations and business process improvement. He holds a master's degree in business administration from Kennesaw State University.

#### **About Enovis**

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit [www.enovis.com](http://www.enovis.com).

---

\*\*\*

Derek Leckow  
Vice President, Investor Relations  
Enovis Corporation  
+1-302-252-9129  
investorrelations@Enovis.com

Source: Enovis Corporation